|
|||||
|
|
Lessons from a pilot study of transfer factor in chronic fatigue syndrome |
|
| Authors: | Dr Caterina De Vinci Paul H Levine Giancarlo Pizza Hugh H Fudenberg Perry Orens Gary Pearson Dimitri Viza |
| Institution: | (1) Georgetown University, Washington DC, USA;(2) NeuroImmuno Therapeutics Foundation, Spartanburg, SC, USA;(3) Great Neck, New York, NY, USA;(4) Laboratoire d’Immunobiologie, URA 1294 CNRS, Faculté de Médecine, Paris, France;(5) Immunodiagnosis and Immunotherapy Unit, 1st Division of Urology, Sant’ Orsola-Malpighi Hospital, 40138 Bologna, Italy |
| Abstract: | Transfer Factor (TF) was used in a placebo controlled pilot study of 20 patients with chronic fatigue syndrome (CFS). Efficacy of the treatment was evaluated by clinical monitoring and testing for antibodies to Epstein-Barr virus (EBV) and human herpes virus-6 (HHV-6). Of the 20 patients in the placebo-controlled trial, improvement was observed in 12 patients, generally within 3-6 weeks of beginning treatment. Herpes virus serology seldom correlated with clinical response. This study provided experience with oral TF, useful in designing a larger placebo-controlled clinical trial. |
| Keywords: | CMV chronic fatigue syndrome EBV herpes viruses HHV-6 transfer factor |
| 本文献已被 SpringerLink 等数据库收录！ | |